drugset
Drugs / Pyridoxal Isonicotinoyl Hydrazone
last change Mar 1995 re-read 3 minutes ago

Pyridoxal Isonicotinoyl Hydrazone

also known as PIH

Small molecule

Developed for
anemia, hypochromic microcytic with iron overload · beta thalassemia · disorder of iron metabolism and transport
Investigated by
Case Western Reserve University · National Heart, Lung, and Blood Institute (NHLBI)

Trials 1

today NCT00000588 · Ph 2
198919901991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT00000588 Jun 1989 → Mar 1993 anemia, hypochromic microcytic with iron overload, beta thalassemia, disorder of iron metabolism and transport Case Western Reserve University Completed No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as Pyridoxal Isonicotinoyl Hydrazone “Chelation Therapy of Iron Overload With Oral Pyridoxal Isonicotinoyl Hydrazone” NCT00000588 ↗
Known as PIH “orally-administered pyridoxal isonicotinoyl hydrazone (PIH)” NCT00000588 ↗
Modality Small molecule — CHEMBL103111 ↗
Route Oral “orally-administered pyridoxal isonicotinoyl hydrazone (PIH)” NCT00000588 ↗